A5062679115- Phagocytosis and Immune Regulation
- Fibroblast Growth Factor Research
- Immune cells in cancer
- Renal cell carcinoma treatment
- Eosinophilic Disorders and Syndromes
- Advanced Breast Cancer Therapies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pediatric Pain Management Techniques
- Gastrointestinal Tumor Research and Treatment
- Neonatal Respiratory Health Research
- Breast Lesions and Carcinomas
- Infant Development and Preterm Care
- Angiogenesis and VEGF in Cancer
- Cancer-related Molecular Pathways
- Neuroblastoma Research and Treatments
- Pancreatic and Hepatic Oncology Research
- Metastasis and carcinoma case studies
Eisai (Japan)
2020-2025
German Orient Foundation
2017
Abstract Combination therapies consisting of immune checkpoint inhibitors plus anti-VEGF therapy show enhanced antitumor activity and are approved treatments for patients with renal cell carcinoma (RCC). The immunosuppressive roles VEGF in the tumor microenvironment well studied, but those FGF/FGFR signaling remain largely unknown. Lenvatinib is a receptor tyrosine kinase inhibitor that targets both VEGFR FGFR. Here, we examine anti-PD-1 mAb combined either lenvatinib or axitinib,...
Fibroblast growth factor (FGF) signaling plays a crucial role in several cellular functions cancer cells. Tasurgratinib, formerly known as E7090, is an orally available FGF receptor (FGFR)1-3 selective inhibitor. Here, we present the effects of tasurgratinib on resistance to CDK4/6 inhibitors and endocrine therapy (ET) preclinical model. Estrogen (ER)+ breast (BC) patient-derived xenograft (PDX) models harboring ESR1 wild-type or mutation were used animal models. An vitro cell proliferation...
Background/Aim: Cholangiocarcinoma (CCA) is an aggressive tumor with limited treatment options especially in 2nd line or later treatments. Targeting fibroblast growth factor receptor (FGFR) 2 has recently emerged as a promising option for patients CCA harboring FGFR2-fusion. This study investigated the antitumor activities of tasurgratinib orally available FGFR1-3 inhibitor, preclinical FGFR2-driven models. Materials and Methods: Antitumor were examined vitro vivo using NIH/3T3 cells...
Neonatal pain management guidelines have been released; however, there is insufficient systematic institutional support for the adoption of evidence-based in Japan.To evaluate impact a collaborative quality improvement program on implementation improvements Japanese neonatal intensive care units (NICUs).Seven level III NICUs participated based an Institute Healthcare Improvement model. The developed practice points and implemented these over 12-month period. Changes were introduced through...
Abstract Innate and adaptive resistance to cancer therapies, such as chemotherapies, molecularly targeted immune-modulating is a major issue in clinical practice. Subpopulations of tumor cells expressing the receptor tyrosine kinase AXL become enriched after treatment with antimitotic drugs, causing relapse. Elevated expression closely associated drug samples, suggesting that plays pivotal role resistance. Although several molecules inhibitory activity have been developed, none sufficient...
Abstract Introduction: The fibroblast growth factor receptor (FGFR) signaling has a crucial role in proliferation, survival, migration, and drug resistance of cancer cells, as well tumor angiogenesis. Moreover, gene alterations FGF/FGFR were reported after treatment CDK4/6 inhibitor endocrine therapy (ET) ER(+)/HER2(-) breast (BC) patients, suggesting mediates to these therapies. E7090, an orally available FGFR1-3 selective inhibitor, is currently under evaluation Phase 2 study patients with...
<p>Supplementary Data Figure S1-S7</p>
<p>Supplementary Data Figure S1-S7</p>
<p>Supplementary Figure S1-S7</p>
<p>Supplementary Figure S1-S7</p>
<div>Abstract<p>Combination therapies consisting of immune checkpoint inhibitors plus anti-VEGF therapy show enhanced antitumor activity and are approved treatments for patients with renal cell carcinoma (RCC). The immunosuppressive roles VEGF in the tumor microenvironment well studied, but those FGF/FGFR signaling remain largely unknown. Lenvatinib is a receptor tyrosine kinase inhibitor that targets both VEGFR FGFR. Here, we examine anti-PD-1 mAb combined either lenvatinib or...
<p>Supplementary materials and methods</p>
<p>Supplementary materials and methods</p>